Effects of renin‐angiotensin blockade and APOL1 on kidney function in sickle cell disease

Abstract

[ 1] Treatments for SCD-related kidney disease have been adopted from therapies used to treat other causes of kidney disease (angiotensin converting enzyme-inhibitor or angiotensin receptor blocker [ACEi/ARB]), although their safety and effects on kidney function are not clear. [ 3] The potential benefit for ACEi to reduce the risk of kidney disease progression in African Americans with the APOL1 kidney risk variants has been observed in the African American Study of Kidney Disease and Hypertension (AASK) cohort. Model 1 + APOL1 kidney risk status. Because clinical data are limited, current American Society of Hematology guidelines have conditional recommendations with low levels of certainty for the use of ACEi/ARB to treat sickle cell nephropathy.